Final - August 30, 2021 MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Centers for Disease Control and Prevention Atlanta, Georgia 30329 August 30, 2021 AGENDA ITEM PRESIDER/PRESENTER(s) Monday, August 30, 2021 10:00 Welcome & Introductions Dr. Grace Lee (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC) 10:15 Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Dr. Matthew Daley (ACIP, WG Chair) BNT-162b2 COVID-19 vaccine BLA safety and efficacy data Dr. John Perez (Pfizer-BioNTech) 11:00 Break 11:15 Public Comment 11:45 Break 12:00 Safety update for COVID-19 vaccines: VAERS Dr. John Su (CDC/NCEZID) Safety update for COVID-19 vaccines: VSD Dr. Nicola Klein (Kaiser Permanente Northern California) VaST assessement Dr. Grace Lee (ACIP, VaST Co-chair) Benefit-risk discussion for use of Pfizer-BioNTech COVID-19 vaccine in individuals Dr. Hannah Rosenblum (CDC/NCIRD) ≥16 years of age 1:30 Break 1:45 GRADE: Pfizer/BioNTech COVID-19 vaccine Dr. Julia Gargano (CDC/NCIRD) Evidence to Recommendations Framework: Pfizer-BioNTech COVID-19 vaccine Dr. Kathleen Dooling (CDC/NCIRD) 2:45 Break 3:00 Discussion VOTE Pfizer/BioNTech COVID-19 vaccine for individuals ≥16 years of age Dr. Kathleen Dooling (CDC/NCIRD) 3:30 Break 3:45 Framework for COVID-19 booster doses Dr. Sara Oliver (CDC/NCIRD) Discussion 4:30 Adjourn
Acronyms CDC Centers for Disease Control and Prevention CMS Centers for Medicare and Medicaid Services COVID-19 Coronavirus disease 2019 EtR Evidence to Recommendations Framework FDA Food and Drug Administration GRADE Grading of Recommendations Assessment, Development and Evaluation HRSA Health Resources and Services Administration IHS Indian Health Service NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID] NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID] NIAID National Institute of Allergy and Infectious Diseases OIDP Office of Infectious Disease and HIV/AIDS Policy SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 WG Work Group WHO World Health Organization VE Vaccine Effectiveness
page 1 of 1